Young Investigators Awards  by unknown
JACC February 21, 2006 ABSTRACTS - Young Investigators Awards  381A 
Young Investigators A
w
ards
Roche for NT-proBNP. We sought to assess and compare these assays as biomarkers 
for mortality in a strategy to enhance efforts at primary prevention. Further, we sought to 
characterize the echocardiographic and clinical phenotype of those individuals who are at 
greatest risk for mortality as determined by plasma BNP or NT-proBNP.
Methods: We utilized the Rochester Epidemiology Project (Olmsted Co, MN), a large 
community-based cohort of 2042 subjects. We excluded those with HF (Framingham 
criteria) or RF (Cr > 2.0mg/dL). In the remaining 1991 subjects thorough echocardiographic 
and clinical data were recorded. Median follow-up for mortality was 5.6 years.
Results: Analysis according to tertiles as well as a continuous variables show both BNP 
assays and NT-proBNP to be signﬁcantly predictive of mortality. We show an incremental 
and signiﬁcant increase in the prevalence of all clinical and echocardiographic 
phenotypes examined, including left ventricular hypertrophy and diastolic dysfunction, 
with increasing BNP and NT-proBNP levels. However, even after adjustment for all clinical 
and echocardiographic phenotypes, the NT-proBNP and Biosite assays remain signiﬁcant 
predictors of mortality. Further sequential modeling suggests that NT-proBNP is a more 
robust marker for mortality than plasma BNP by either Biosite or Shionogi assays.
Conclusions: We report in a large, well characterized community-based cohort, free of 
HF and RF, the ﬁrst study to compare NT-proBNP and BNP assays in the same population-
based cohort as biomarkers for mortality. Speciﬁcally, the NT-proBNP and Biosite BNP 
assays and to a less extent the Shionogi BNP assay remain predictive of mortality even 
after adjustment for clinical phenotypes and echocardiographic abnormalities. This study 
conﬁrms the potential use of these peptides as biomarkers for future events.
9:45 a.m.
408-8 Impact of Heart Failure Medications on the Incidence of 
Ventricular Arrythmias in Patients of Congestive Heart 
Failure Who Have Implantable Cardiac Deﬁbrillator: A 
Follow-Up of 374 Patients
Saugato Sanyal, Beth Israel Medical Center, New York, NY
Background: Heart failure (CHF) medications have been hypothesized to ameliorate 
arrhythmogenic neuro-hormonal changes. Long term data examining their true impact on 
arrhythmia incidence in CHF is unknown.
Methods: Deﬁbrillator (ICD) logs and clinical records of ICD follow up patients with 
Ejection Fraction (EF) less than 40% were analyzed, including medications at implant 
and at two follow up encounters. Arrhythmia logs were corroborated with strip analysis as 
available. Generalized Linear Modeling was used to look at the association between CHF 
medication use and arrhythmias.
Results: 374 patients with 26.3 ± 20.8 months of follow up and an EF of 27± 7% were 
included. There were155 diabetics(44%), 321 hypertensives, and 70(19 %) had chronic 
renal failure (serum creatinine> 2.0mg/dl ). 266 (71%) had ischemic cardiomyopathy. 
Utilization of CHF medications and incidence of arrhythmias as a function of CHF 
medication use is shown in the table. P values were based on actual number of events 
per patient after controlling for other drugs and risk factors.
Table : Rates of Utilization of Various CHF Medications and Incidence of 
Ventricular Arrhythmias
Medications with (% 
of patients on meds)
Prevalence of Ventricular 
Fibrillation in those on vs (not 
on meds)
P value
(Total Events, 
Multivariate)
Prevalence of Ventricular 
Tachycardia in those on vs (not 
on meds )
P Value
(Total Events, 
multivariate)
Spironolactone 
(34%) 17% vs (21%) 0.0134 29% vs (44%) 0.<0001
Loop Diuretics 
(62%) 25% vs (11%) 0.002 45% vs (30%) 0.008
ACEI/ARB 
(64%) 19% vs(20.6%) 0.22 42% vs (36%) 0.21
Any Beta 
Blocker (72%) 22% vs (16%) 0.42 40% vs (38%) 0.56
Carvedilol 
(40%) 19% vs (21%) 0.53 40% vs (39%) 0.67
Digoxin (48%) 24% vs (15%) 0.28 44% vs (35%) 0.16
Conclusions: In this select group of CHF patients:
1) Spironolactone reduced the number and prevalence of Ventricular arrhythmias while 
Loop Diuretics increased it.
2) ACEI, Digoxin and Beta Blockers, including Carvedilol did not impact rates of VT/VF.
3) In clinical practice, manipulations of the Aldosterone system seem to have a prominent 
impact on arrhythmogenecity
10:00 a.m.
408-9 Intracoronary Boluses of Adenosine and Sodium 
Nitroprusside in Combination Reverses Slow/No 
Reﬂow During Angioplasty: A Clinical Scenario of 
Experimental Preconditioning
Hetal D. Shah, Ramesh K. Goyal, Keyur H. Parikh, L M College of Pharmacy, 
Ahmedabad, India, The Heart Care Clinic, Ahmedabad, India
Background: “No-reﬂow” (NR) or “impaired ﬂow”, the absence or decrease in blood ﬂow 
despite patent epicardial vessel after percutaneous coronary interventions (PCI) is a 
serious complication resulting in increased incidences of morbidity, myocardial infarction 
and mortality. The study aims to evaluate the intracoronary(IC) combination of adenosine 
and sodium nitroprusside(ADE-SNP) in NR phenomenon during PCI.
Methods:75 high risk acute coronary syndrome patients who underwent PCI with 
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408-5 Haptoglobin Genotype Determines Myocardial Infarct 
Size in Diabetic Mice
Shany Blum, Julia Guetta, Rachel Miller-Lotan, Rabea Asleh, Roy Asaf, Ran Kremer, 
Franklin G. Berger, Nina S. Levy, Andrew P. Levy, Technion-Israel Institute of Technology, 
Haifa, Israel
Background. The haptoglobin (Hp) 2 allele is associated with increased myocardial 
infarction (MI) size in individuals with Diabetes Mellitus (DM). We sought to recapitulate 
this association in transgenic mice and to understand its mechanistic basis.
Methods and Results. MI was produced with a 45 minute occlusion of the left anterior 
descending artery followed by 1 hour of reperfusion in DM and non-DM C57Bl/6 mice 
carrying the Hp 1 allele or the Hp 2 allele. We found that MI size was signiﬁcantly larger 
in DM mice with the Hp 2 allele as compared to the Hp 1 allele (44.3+/-9.3 % vs. 21.0+/-
4.0 %, p<0.04). Redox active labile plasma iron (LPI) and the anti-inﬂammatory cytokine 
interleukin-10 (Il-10) are known to play major roles in determining the extent of myocardial 
injury after myocardial ischemia and reperfusion and were therefore measured at the end 
of the reperfusion interval. LPI was signiﬁcantly increased in Hp 2 as compared to Hp 1 
mice (0.45 ± 0.11 uM vs. 0.14 ± 0.05 uM, p =0.02). Il-10 was signiﬁcantly increased in Hp 
1 as compared to Hp 2 mice (441 ± 101 pg vs. 62 ± 51 pg; p=0.01). In vitro studies with 
puriﬁed Hp and peripheral blood mononuclear cells demonstrated that Hp 1-1 resulted in a 
signiﬁcantly greater induction of Il-10 than Hp 2-2. Conclusions. Diabetic mice containing 
the Hp 2 allele have larger infarcts similar to that observed in man. This may be mediated 
by Hp genotype dependent differences in the production of LPI and Il-10.
9:15 a.m.
408-6 Novel Predictor of Prognosis From Exercise Testing: 
Heart Rate Variability Response to the Exercise 
Treadmill Test
Frederick E. Dewey, James Freeman, Greg Engel, Raul Pinoviedo, Nayana Abrol, 
Natasha Ahmed, Jonathan Myers, Victor F. Froelicher, Stanford University, Palo Alto, CA, 
Palo Alto VA Health Care System, Palo Alto, CA
Background: While heart rate variability (HRV) has been demonstrated to have 
prognostic value when performed during ambulatory monitoring, its value has not been 
assessed during the standard exercise test. We evaluated several variables including 
spectral analysis parameters of heart rate variability (HRV) data during and after standard 
exercise testing (EI-HRV).
Methods: Spectral analysis was performed on R-R interval data taken from 1302 subjects 
(95% male, mean age 58) during the ﬁrst and last two minutes of exercise and the ﬁrst 
two minutes of recovery. Cox survival analysis including clinical and exercise testing 
parameters (age, METs, ST depression, heart rate recovery, heart rate reserve, smoking 
history, history of CHF, prior known coronary intervention, and prior MI) as well as EI-
HRV parameters was performed for cardiovascular and all-cause mortality endpoints that 
accrued during the 4.5 year mean follow-up.
Results: In contrast to investigations of the prognostic power of resting HRV parameters, 
we found that increased time- and frequency domain parameters during peak exercise and 
recovery were associated with higher risks for all-cause and cardiovascular death. SDNN 
during peak exercise and recovery and the high frequency HRV component during recovery 
were stronger predictors of cardiovascular death than all other clinical and exercise testing 
variables under consideration (adjusted Hazard ratio (HR) 1.6, 95% CI 1.2-2.0, p=0.003, 
HR 1.6 95% CI 1.1-2.2, p=0.005, and HR 1.6, 95% CI 1.2-2.2, p=0.003 for an increase 
of one SD in log SDNN during peak exercise, log SDNN during recovery, and log high 
frequency power during recovery, respectively). Age and peak METs were the only other 
signiﬁcant independent predictors of both all-cause and cardiovascular death.
Conclusions: Log SDNN during peak exercise and recovery and log HF power during 
recovery from standard exercise testing strongly predict both cardiovascular and all-
cause death independent of traditional risk factors in our study population. These results 
invite new explanations of the relationship between spectral analysis parameters and 
autonomic modulation of heart rate in the setting of exercise.
9:30 a.m.
408-7 The Predictive Value of B-type Natriuretic Peptide for 
Mortality in a Community-Based Cohort Free of Heart 
Failure
Paul M. McKie, Richard J. Rodeheffer, Alessandro Cataliotti, Fernando L. Martin, Lynn 
H. Urban, Douglas W. Mahoney, Steven J. Jacobsen, Margaret M. Redﬁeld, John 
C. Burnett, Jr., Mayo Clinic, Rochester, MN, The Stanley J Sarnoff Endowment for 
Cardiovascular Research, Great Falls, VA
Background: Recent studies have reported that in the general population, in the absence 
of heart failure (HF) and renal failure (RF), plasma BNP has prognostic value for mortality. 
NT-proBNP is the inactive fragment secreted with mature BNP. Circulating BNP and NT-
proBNP are measured by three widely used assays: Shionogi and Biosite for BNP and 
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evidence of initial less than TIMI III ﬂow or developed deterioration in TIMI ﬂow during the 
procedure were randomized to prophylactic administration of multiple boluses of IC saline 
(n=25), adenosine (ADE: 12µg/bolus; n=25) or the combination (n=25) of adenosine 
(12µg/bolus) and sodium nitroprusside (50µg/bolus), sequentially. Assessment of TIMI 
and the TMP grade was done by the two independent cardiologists to avoid inter-observer 
bias. Major Adverse Cardiac Events (MACE) were assessed at the end of six months.
Results: Slow or NR was persistent in 16 (70%) patients receiving saline, 8 (31%) patients 
receiving ADE and 1 (4%) patient receiving ADE-SNP. IC injection with saline did not 
produce any improvement in TIMI ﬂow or TMP grade. IC ADE signiﬁcantly improvedTIMI 
ﬂow (1.15±0.4 to 2.15±0.3, p<0.01) and TMP grade(1.19±0.3 to 2.12±0.3, p<0.01). ADE-
SNP group also showed a signiﬁcant improvement in TIMI ﬂow (1.2±0.3 to 2.81±0.1, 
p<0.001) and TMP grade (1.12±0.3 to 2.77±0.1, p<0.001) and these improvements being 
signiﬁcantly more as compared to ADE treated pateint (p<0.05) The crossover of patients 
with NR in saline group to ADE-SNP was associated with reestablishment of TIMI II in 2 
(12.5%) and TIMI III in 14 (87.5%) patients, while the crossover of those in ADE group to 
ADE-SNP was associated with reestablishment of TIMI II ﬂow in 2 (25%) and TIMI III in 
6 (75%) patients. Six months follow up showed 0.91% Re-MI in the ADE-SNP arm while 
1.09% repeat PCI and 2.19% deaths in the saline arm.
Conclusions: Combination therapy of ADE and SNP is safe and provides better 
improvement in coronary ﬂow compared to IC ADE alone in case of impaired ﬂow during 
coronary interventions with an additional reduction in MACE.
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410-5 Calcium Dynamics and the Mechanisms of Vulnerability 
and Deﬁbrillation in Langendorff-Perfused Rabbit 
Ventricles
Gyo-Seung Hwang, Hideki Hayashi, Liang Tang, Masahiro Ogawa, Heidy Hernandez, 
Alex Y Tan, Hrayr S Karagueuzian, James N Weiss, Shien-Fong Lin, Peng-Sheng Chen, 
Cedars-Sinai Medical Center, LA, CA, David Geffen School of Medicine, LA, CA
Background: The relation between intracellular calcium (Cai) dynamics and the 
mechanisms of shock-induced ventricular ﬁbrillation (VF) (vulnerability) and deﬁbrillation 
(DF) is unclear.
Methods: In 17 Langendorff-perfused rabbit ventricles, we simultaneously mapped 
membrane potential (Vm) and Cai during upper limit of vulnerability (ULV) testing by shock 
on T, and during DF threshold (DFT) testing with up-down protocol using biphasic shocks. 
We analyzed 89 episodes of VF induction by shocks on T and 173 episodes of attempted 
deﬁbrillation. We selected for analyses 80 episodes with postshock activation that started 
from the center of the mapped region.
Results: The ULV and the DFT were 217±81 V and 266±79 V, respectively (p=NS). 
Shock-induced activation resulted in a heterogeneous postshock distribution of Cai with 
the emergence of an area characterized with low Cai surrounded by areas of elevated 
Cai (“Cai sinkhole”). These Cai sinkholes emerged on the Cai map 43±16 ms after the 
shock. The ﬁrst postshock Vm activation always originated from the sinkhole hole 73±20 
ms after shock, and spread in a centrifugal pattern. Sinkholes were present in type-B but 
not type-A successful deﬁbrillation. For shock on T, a Cai sinkhole was present 46±40 ms 
after the shock. The sinkhole was followed 30±19 ms later by propagated wavefronts that 
arose from the sinkhole during late phase 3 of action potential, leading to a spiral wave 
that initiates VF. Assuming that the membrane potential varied from -75 mV to +15 mV in 
S1-paced beats, the take off potential of the ﬁrst postshock activation was -46.2±0.7 mV. 
No sinkhole was present at shock strengths above the ULV. Thapsigargin (200 nM) and 
ryanodine (5 µM) increased APD90 from 176±40 ms to 273±46 ms (P= 0.009), sinus cycle 
length from 492±281 ms to 997±244 ms (p=0.02), decreased ULV from 393±137 V to 
171±99 V (p=0.007) and DFT from 429±141 V to 271±202 V (p=0.005).
Conclusions: We conclude that Cai dynamics is important in the mechanisms of 
vulnerability and deﬁbrillation. The formation of Cai sinkhole in the immediate postshock 
period appears necessary for the initiation of postshock activation perhaps mediated by 
a Cai dependent mechanism.
11:15 a.m.
410-6 Aithon, a Novel Factor for Actin Dynamics, Regulates 
Microvascular Endothelial and Inﬂammatory Cells 
Function
Koji Ikeda, Ramendra Kundu, Shoko Ikeda, Thomas Quertermous, Stanford University, 
Palo Alto, CA, Kyoto Prefectural University of Medicine, Kyoto, Japan
Background: Actin cytoskeleton reorganization is a fundamental process for actin-based 
cellular functions such as cytokinesis, phagocytosis and chemotaxis. Regulating actin 
dynamics is therefore a very effective approach to control endothelial and inﬂammatory 
cells function, and to treat cardiovascular diseases such as myocardial infarction. 
However, it has been difﬁcult to control actin dynamics effectively only in the targeted 
cells because common molecular systems are used in variety types of cells.
Methods and results: During microarray analysis aimed at isolating endothelial cell 
speciﬁc gene, we identiﬁed previously uncharacterized glia maturation factor-gamma, 
which we newly named aithon (ATN), is expressed highly preferentially in microvascular 
endothelial cells. We found ATN is selectively expressed in microvascular endothelial cells 
and inﬂammatory cells in adults while it is expressed predominantly in blood islands on 
the yolk-sac where endothelial and hematopoietic cells develop simultaneously during 
embryogenesis. ATN preferentially localized in the F-actin-rich membrane rufﬂes, 
suggesting its function in actin dynamics. ATN was phosphorylated at N-terminal serine, 
and its phosphorylation was enhanced by co-expression of dominant active Rac1 and 
Cdc42. ATN was associated with F-actin, and this association was regulated by its 
phosphorylation. Interestingly, stable expression of ATN remarkably enhanced stimulus-
responsive lamellipodia formation. Furthermore, we demonstrated the interaction of ATN 
with Arp2/3 complex, a key regulator of stimulus-responsive actin polymerization. In 
functional studies, expression of ATN enhanced actin-based cellular functions such as 
migration and tube-formation in endothelial cells. Moreover, we found ATN expression was 
increased in the infracted hearts, suggesting its in vivo function in myocardial infarction.
Conclusion: Our data deﬁne a novel pathway in the regulation actin-based cellular 
functions in microvascular endothelial cells and inﬂammatory cells. Regulating ATN 
function could be a powerful tool to modulate pathophysiology of cardiovascular diseases 
such as myocardial infarction.
11:30 a.m.
410-7 Paracrine Release of Transforming Growth Factor-Beta 
Inhibits Endocardial Thrombomodulin Expression in 
Acute Heart Failure
Navin K. Kapur, Clayton B. Deming, Ce Bian, Sunil Kapur, Hunter C. Champion, 
Kevin J. Donohue, David A. Kass, Jeffrey J. Rade, Johns Hopkins School of Medicine, 
Baltimore, MD
Background: Thromboembolic events are a major cause of morbidity and mortality in 
heart failure. We have found that endocardial expression of thrombomodulin (TM), a critical 
member of the protein C anticoagulant pathway, is markedly decreased in the left atrium (LA) 
of rats in acute heart failure. Transforming growth factor-beta (TGF-β), a stretch-responsive 
cytokine, is known to inhibit TM expression in cultured endothelial cells. We hypothesize that 
induction of TGF-β inhibits endocardial TM expression in acute heart failure. 
Methods & Results: Acute LA pressure overload was created in Wistar rats (n=10/
group) by aortic banding. Compared to sham controls, left ventricular diastolic pressure 
increased by >350% (4.5±1.7 versus 17.4±2.9 mmHg, p<0.001) four days after banding. 
By quantitative PCR, LA TM expression was reduced 60±7% (p=0.01), while TGF-β 
expression increased 200±20% (p<0.001) versus controls. Administration of an anti-TGF-
β1 antibody, but not an isotype control, completely abolished TM downregulation in the LA 
(p <0.005). To determine the source of TGF-β, human atrial endocardial cells (HAEC) and 
aortic smooth muscle cells (HASMC) were subjected to 10% cyclic strain for 24h using a 
Flexcell apparatus. Direct stretching of HAEC did not signiﬁcantly alter TGF-β expression 
and even resulted in increased TM expression. In contrast, stretched HASM increased 
both TGF-β gene (259±49%; p=0.02) and antigen levels (158±27%; p<0.005) compared 
to static controls. To determine if paracrine release of TGF-β modulates endocardial TM 
expression, HAEC were cultured on stationary ﬁlters suspended in wells of Flexcell plates 
containing HASMC. Co-incubation with stretched HASM caused a 60±16% (p=0.01) 
reduction in HAEC TM expression compared to co-incubation with unstretched HASMC. 
TM downregulation in HAEC was completely prevented by addition of an anti-TGF-β1 
antibody to the culture medium. Conclusion: TM expression by the atrial endocardium 
is markedly reduced in acute heart failure, an effect that is likely mediated by paracrine 
release of TGF-β from adjacent myocytes. Inhibition of TGF-β may represent a novel 
approach for preventing thromboembolus formation in heart failure.
11:45 a.m.
410-8 Stimulation of Endothelial Progenitor Cells With 
Granulocyte Macrophage Colony Stimulating Factor 
Improves Endothelial Dysfunction in Patients With 
Peripheral Arterial Disease
Veerappan Subramaniyam, Uma Reddy, Diane Sutcliffe, Wayne Harris, Sonya LeFever, 
Edmund Waller, W. Robert Taylor, Paul Kolm, R. Wayne Alexander, Arshed Quyyumi, 
Emory University School of Medicine, Atlanta, GA
Background: Endothelial dysfunction is an important determinant of risk and appears 
to result from an imbalance between injury and repair of the endothelium. Bone marrow 
derived endothelial progenitor cells (EPCs) contribute to re-endothelialization after 
vascular injury, and we recently found that endothelial function was strongly correlated 
with circulating EPC counts. We hypothesized that endothelial dysfunction in peripheral 
arterial disease (PAD) will improve as a result of mobilization of EPCs from the bone 
marrow with granulocyte macrophage colony stimulating factor (GM-CSF). 
Methods: In a double-blind placebo controlled study, we randomized 45 PAD patients 
to either GM-CSF or placebo in a 2:1 schema, respectively. Each cohort of 15 patients 
received 3, 6 or 10mcg/kg dose of GM-CSF or placebo, thrice weekly for 2 weeks. 
Safety labs, circulating EPC counts by colony formation assay, CD34+ cells by FACS 
analysis, and endothelium-dependent and -independent function by brachial ultrasound 
were measured.
Results: GM-CSF treatment increased total leucocyte count (p=0.003) with a peak at 
2 weeks. A similar increase in EPC-CFU corrected for total leucocyte count (753±521 
to1154±794, p=0.02) and circulating CD34+cells (2120±2124 to 3761±3285 cells/ml, 
p<0.01) was observed. These changes were not observed in the placebo cohort. There 
was also no signiﬁcant difference between the 3 GM-CSF dose groups. Endothelial 
function, measured as brachial FMD was severely depressed at baseline and 
improved after GM-CSF therapy (2.9±3 % to 4.6±3.3%, p=0.01), but was unchanged 
in the placebo group. No signiﬁcant change in endothelium-independent dilation with 
nitroglycerin was observed. 
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Conclusions: GM-CSF mobilizes EPCs into the circulation of patients with PAD. This is 
associated with selective improvement of endothelial dysfunction and suggests that EPCs, 
by enhancing repair may contribute to endothelial healing. Whether stem cell mobilization 
can be used to improve vascular function and reduce the risk of atherosclerosis needs 
further study.
Noon
410-9 New Hypothesis for Vulnerable Plaque Rupture: 
Local Stress Concentration Around Single Calciﬁed 
Macrophages in the Thin Fibrous Cap
Savvas S. Xanthos, Yuliya Vengrenyuk, Stéphane Carlier, Peter Ganatos, Lane Gilchrist, 
Frank Kolodgie, Renu Virmani, Sheldon Weinbaum, The City College of CUNY, New 
York City, NY, Cardiovascular Research Foundation, New York City, NY
Background: Mechanisms responsible for the sudden conversion of a rupture-prone 
plaque to a life threatening atherothrombotic lesion leading to acute coronary syndromes 
are not fully understood. Paradigms remain: (i) why does a plaque rupture in its mid-
portion when ﬁnite element models predict maximum tissue stress at the shoulder? (ii) 
why at physiological stress (blood pressure) lower than modeled from tissue properties? 
We investigated the mechanical effects of minute impurities in thin cap ﬁbroatheroma to 
solve these paradigms.
Methods: Looking for minute cellular level calciﬁcations or iron deposits formed in the 
ﬁbrous cap (e.g. by smooth muscle cell or macrophage apoptosis near the necrotic core 
or by erythrocyte phagocytosis) we used stains speciﬁc for both calcium (Von Kossa) and 
iron (Hemosiderin) and reviewed histological sections of thin cap ﬁbroatheroma, some 
of them ruptured. A 3D confocal microscopy technique was also developed for detecting 
and verifying the existence of the aforementioned inclusions with the use of ﬂuorescence 
stains (Alizarin Red S.) speciﬁc to calcium. A theoretical model of a minute spherical 
inclusion (10 micron in diameter) was ﬁnally developed and solved and further veriﬁed 
by a FEM calculation.
Results: We found multiple cases of calciﬁcations and iron deposits in thincaps. These 
minute calciﬁcations and iron deposits were, heretofore, ignored because they fell below 
the sensitivity threshold of intravascular ultrasound (IVUS) or other available in vivo 
imaging techniques and hence their existence went unrecognized. The theoretical model 
and Finite Element Method solution revealed that these approximately 10 micron rigid 
inclusions can intensify the local circumferential stress nearly two fold, to values in excess 
of the reported critical rupture stress of approximately 600 kPa when the cap thickness is 
equal to or less than 65 microns.
Conclusions: The presence of minute cellular level hard inclusions in thin-cap 
ﬁbroatheroma lesions can facilitate their rupture. This novel hypothesis might explain 
remaining paradigms of the triggering events leading to vulnerable plaque rupture.
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413-4 Pre-hospital Wireless Transmission of 
Electrocardiograms to a Cardiologist via Hand-held 
Device for Patients With Acute Myocardial Infarction
George L. Adams, Paul Campbell, John Adams, David G. Strauss, Janet Patterson, 
Karen Wall, Charles Maynard, Dwayne Young, Benjamin Lee, Galen Wagner, Duke 
University Medical Center, Durham, NC
Background: Percutaneous coronary intervention (PCI) for patients with ST-segment 
elevation myocardial infarction (STEMI) signiﬁcantly reduces morbidity and mortality if 
performed within the ﬁrst two hours of symptom onset. However, the American College of 
Cardiology/American Heart Association (ACC/AHA) proposed guidelines for PCI door-to-
balloon time (<90 minutes) in patients with STEMI is a goal infrequently accomplished.
Methods: We conducted a prospective case-control pilot study, enrolling 277 suspected 
STEMI patients either self-transported or transported by emergency medical services to 
NorthEast Medical Center (Concord, NC) for primary PCI. The purpose of this study was 
to test the hypothesis that pre-hospital wireless transmission of an electrocardiogram 
(ECG) to a cardiologist’s hand-held device results in reduced emergency department 
door-to-reperfusion time. In this study we compared patients whose ECG was successfully 
transmitted during the intervention phase to: (a) pre-intervention phase EMS transported 
patients, (b) intervention phase self-transported patients, and (c) intervention phase 
patients for whom wireless transmission failed.
Results: During the pre-intervention phase (2001 to 2003), 48 patients were enrolled. 
During the intervention phase (2003 to 2005), 101 self-transport patients were enrolled, 
and 24 patients with successful wireless ECG transmission were enrolled, as well as 19 
patients for whom wireless transmission failed. The median door to reperfusion time for 
the patients with successful ECG transmission was 50 minutes, a time signiﬁcantly faster 
than the pre-intervention group time of 101 minutes (p<0.0001), the intervention phase 
self-transport patients of 96 minutes (p<0.0001), and the failed transmission group time 
of 78 minutes (p<0.0001).
Conclusions: Pre-hospital wireless ECG transmission directly to a cardiologist’s hand-
held device signiﬁcantly reduced emergency department door-to-reperfusion time, 
achieving the recommended ACC/AHA goal for patients with STEMI.
2:15 p.m.
413-5 Cost-Effectiveness of ICD Therapy and Risk 
Stratiﬁcation With Microvolt T Wave Alternans Testing in 
the MADIT-II Eligible Population
Paul S. Chan, Kenneth Stein, Theodore Chow, Mark Fendrick, J. T. Bigger, Sandeep 
Vijan, University of Michigan Medical Center, Ann Arbor, MI, Ohio Heart and Vascular 
Center, Cincinnati, OH
Background: Implantable Cardioverter-Deﬁbrillators (ICDs) have been shown to prevent 
mortality in the MADIT-II population. Microvolt T-Wave Alternans (MTWA) testing has 
been shown to be effective in risk stratifying MADIT-II eligible patients at risk for death.
Objectives: To compare the cost-effectiveness of ICD placement with and without risk 
stratiﬁcation with MTWA testing in the MADIT-II population.
Methods: Based on published data and hospital accounting information, cost-
effectiveness of 3 therapeutic strategies in MADIT-II eligible patients were assessed using 
a Markov model: 1) ICD placement in all; 2) ICD placement in patients who test non-
negative with MTWA testing; and 3) medical management. Outcomes of expected cost, 
quality-adjusted life years (QALYs), and incremental cost-effectiveness were determined 
for patient lifetime.
Results: Under base-case assumptions, providing ICDs only to those who test MTWA 
non-negative produced a gain of 1.12 QALYs at an incremental cost of $60,100 when 
compared to medical therapy, resulting in an incremental cost-effectiveness ratio of 
$53,900/QALY. When compared with a MTWA risk stratiﬁcation strategy, placing ICDs 
in all patients resulted in an incremental cost-effectiveness ratio of $96,700/QALY. 82% 
of the total potential beneﬁt of ICDs was achieved by implanting ICDs in the 67% of 
patients who tested MTWA non-negative. Results were most sensitive to the effectiveness 
of MTWA as a risk stratiﬁcation tool, MTWA negative screen rate, cost and efﬁcacy of ICD 
therapy, cost of annual care, and patient risk for arrhythmic death.
Conclusion: Risk stratiﬁcation with MTWA testing in MADIT-II patients improves the cost-
effectiveness of ICDs. Implanting deﬁbrillators in all MADIT-II type patients, however, is not 
cost-effective, with one-third of patients deriving little additional beneﬁt at great expense.
2:30 p.m.
413-6 Association of Cystatin C With Ischemia in Patients 
With Coronary Heart Disease: Results From the Heart 
and Soul Study
Rajat Deo, Michael G. Shlipak, Joachim H. Ix, Sadia Ali, Nelson B. Schiller, Mary A. 
Whooley, University of California, San Francisco, San Francisco, CA, VA Medical Center, 
San Francisco, CA
Background: Cystatin C, a novel measure of kidney function, has recently emerged as a 
potent risk factor for heart failure, cardiovascular disease, and death. It is not known why 
higher concentrations of cystatin C are associated with greater cardiovascular morbidity 
and mortality. We sought to determine whether elevated concentrations of cystatin C were 
associated with inducible ischemia in patients with CHD.
Methods: We measured serum cystatin C and performed exercise treadmill testing with 
stress echocardiography in a cross-sectional study of 899 outpatients with CHD.
Results: Among the 241 participants in the highest quartile of cystatin C (>1.30 mg/
L), 38% had inducible ischemia, compared with 13% of those in the lowest quartile of 
cystatin C (<0.92 mg/L) (adjusted OR 2.1, 95% CI, 1.2 to 3.8; p=0.01). However, this 
association differed in participants with and without a history of CABG, as well as in 
users and nonusers of beta blockers and statins (p values for interaction <0.1). Among 
participants without a history of CABG, 35% of those in the highest quartile and 9% of 
those in the lowest quartile of cystatin C had inducible ischemia (adjusted OR 3.05, 95% 
CI, 1.3-6.9; p=0.008). Among participants who were not using beta blockers, 44% of those 
in the highest quartile and 7% in the lowest quartile of cystatin C had inducible ischemia 
(adjusted OR 5.3, 95% CI, 1.8 - 15.5; p=0.002). Among participants who were not using 
statins, 39% of participants in the highest quartile and 4% of those in the lowest quartile 
had inducible ischemia (adjusted OR 10.3, 95% CI, 2.5-43.3; p=0.001). We did not 
observe an association between cystatin C and inducible ischemia among participants 
with a history of CABG or who were treated with either a beta blocker or statin.
Conclusions: Elevated levels of cystatin C are independently associated with inducible 
ischemia among outpatients with stable coronary disease, particularly among those not 
treated with surgical revascularization, beta blockers or statins.
2:45 p.m.
413-7 Trends in Incidence of Atrial Fibrillation 1980-2000 and 
Implications on Projected Prevalence for 2050
Yoko Miyasaka, Marion E. Barnes, Bernard J. Gersh, Stephen S. Cha, Kent R. Bailey, 
Walter Abhayaratna, James B. Seward, Teresa S. M. Tsang, Mayo Clinic, Rochester, MN
Background:  Limited data exists regarding trends in incidence of atrial ﬁbrillation (AF), 
and published projection of AF prevalence for 2050 was based on cross-sectional data.
Methods: Trends in age-adjusted incidence of ECG-conﬁrmed AF in Olmsted County, 
Minnesota were determined for 1980-2000. In conjunction with United States (US) 
Census data on the aging demographics, these incidence trends were utilized to help 
construct model-based prevalence estimates, with projection of the prevalence for the 
from 2000 to 2050.
Results: A total of 4,618 ﬁrst AF cases were diagnosed during 1980-2000. Age- and 
sex-adjusted incidence of AF was 3.1 per 1000 person-years in 1980 and 3.7 per 1000 
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person-years in 2000. Based on Poisson regression adjusting for age and sex, incidence 
of AF increased (P=0.014), with the rate of relative increase of 0.6 % per year but did 
not differ signiﬁcantly between men and women (P=0.84). Based on the size and aging 
demographics of the US Census, the number of persons with AF in 2050 is projected at 
12.1 million. If however, the same rate of increase in age-adjusted incidence continues, 
the projected number will be 15.9 million by 2050 (Fig).
Conclusions: The age-adjusted incidence of AF increased signiﬁcantly in Olmsted 
County, Minnesota during the period 1980-2000. The anticipated changing demographics 
alone lend an alarming projection of the prevalence to over 10 million by 2050. Primary 
prevention of AF is pivotal to curb this evolving epidemic.
3:00 p.m.
413-8 In Acute Coronary Syndromes Should Patients With 
Multi Vessel Coronary Artery Disease Undergo Culprit 
Lesion or Multi Vessel Stenting?
Mehdi Shishehbor, Derek Chew, Inder Singh, Juhana Karha, Michael Lauer, Sorin 
Brener, David Moliterno, Stephen Ellis, Eric Topol, Deepak Bhatt, Cleveland Clinic 
Foundation, Cleveland, OH
Background: The invasive approach is preferred in patients presenting with acute 
coronary syndromes (ACS). However, in this setting the beneﬁt of culprit vessel versus 
multivessel stenting is not clear.
Methods: Patients with unstable angina or non-ST segment acute myocardial infarction 
undergoing PCI that were prospectively followed for at least 12 months were included. 
Culprit lesion was deﬁned by reviewing angiographic report, electrocardiogram, 
echocardiogram, and if available nuclear stress tests. A lesion was considered culprit if 
an obvious thrombus or ruptured plaque were present, or if two of the above diagnostic 
tests pointed to the same coronary territory. All patients had at least 2 vessels with ≥ 50% 
stenosis on diagnostic angiography. Patients with chronic total occlusion and those with 
unidentiﬁable culprit lesion were excluded. Our primary endpoint was 30-day death or MI 
and one year composite endpoint of death, MI, or any revascularization.
Results: From 01/2000 to 01/2003, 1099 patients with ACS and multivessel disease 
underwent PCI with bare metal stenting. Of these, 628 underwent culprit only and 471 
underwent multivessel stenting. Both in univariable and multivariable propensity matched 
analysis, adjusting for age, gender, weight, diabetes, baseline renal insufﬁciency, peripheral 
vascular disease, blood pressure, number of vessels with stenosis ≥ 50%, left ventricular 
ejection fraction, lesion classiﬁcation, glycoprotein IIb/IIIa, and medication use there were 
no differences between the two groups for the 30-day composite endpoint of death or 
myocardial infarction (MI) (HR, 1.31; 95% CI, 0.87-1.96; P=0.192). However, multivessel 
stenting was associated with increased one year death, MI, or revascularization (HR, 
1.34; 95% CI, 1.08-1.65; P=0.007), which was mainly driven by an increased rate of 
revascularization in this group (HR, 1.38; 95% CI, 1.08-1.78; P=0.010).
Conclusions: In patients with multivessel coronary artery disease presenting with ACS 
there seem to be no short term differences in myocardial infraction or death, though there 
is an increased rate of revascularization at 1 year in those undergoing multivessel PCI 
with bare metal stenting.
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